Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.34

0.0%

Nov 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (1157)	12/13/2001 2:32:08 PM
From: Icebrg	Read Replies (1) of 1475

From Biotech Inside - Dr Ron Garren's column at Biospace. Somehow he forgot to mention the name of the company behind the technology. Ice The field of allogenic was big news at the conference. Autologous transplant uses the patients own stem cells so there are no immune reactions such as graft vs. host disease (GVHD). Allogeneic transplant uses stem cells from a matched donor so there is the possibility of GVHD . The concept of a minimal allogenic transplant is taking hold. The old paradigm was to heavily pre-treat patients, killing all the tumor as well as the bone marrow, and then follow with a rescue stem cell transplant. The newer concept is to do a very mild non-ablative conditioning regimen allowing much of the patient bone marrow and tumor to survive but creating enough room for donor stem cells to engraft. This creates a mixed chimeric state in the marrow. The whole treatment is so non-toxic that it can be done as an outpatient. The initial transplant is then followed by infusions of donor immune cells (lymphocytes ), which kills residual leukemia cells without causing graft vs. host disease. The concept is to let the immune response destroy tumor cells instead of trying to destroy them with chemotherapy and radiation. This form of mixed chimeric transplantation is now called a mini-transplant and could easily be done in the near future at smaller community hospitals as an outpatient procedure. The same general concept of a mini transplant offers the possibility of treating sickle cell disease, other hemoglobinopathies, some inherited diseases and maybe even some autoimmune diseases. The biggest obstacle to rapid development of this technology is the fractured bone marrow community in the US. Each center is doing their own thing and it has been almost impossible to do a multi-institutional trial. This may all change next year. biospace.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next